| Enriched cancer pathway | Genes under regulation | P value |
|---|
| Long.term potentiation |
6 genes: RAPGEF3, PPP1R12A, PPP3CA, PRKCA, RPS6KA2, CACNA1C
|
0.0002573 |
| Regulation of actin cytoskeleton |
10 genes: WASF2, CHRM3, FGF2, ITGA2, PPP1R12A, ENAH, PXN, ACTB, PIP5K1B, ACTN1
|
0.0004138 |
| Leukocyte transendothelial migration |
6 genes: RAPGEF3, PRKCA, PTPN11, PXN, ACTB, ACTN1
|
0.003755 |
| Focal adhesion |
8 genes: FYN, ITGA2, LAMA4, PPP1R12A, PRKCA, PXN, ACTB, ACTN1
|
0.00404 |
| Adherens junction |
4 genes: WASF2, FYN, ACTB, ACTN1
|
0.01377 |
| Phosphatidylinositol signaling system |
4 genes: INPP5D, PRKCA, PIP5K1B, SYNJ1
|
0.01719 |
| MAPK signaling pathway |
8 genes: DUSP7, FGF2, MAX, PPP3CA, PRKCA, RPS6KA2, CACNA1C, CACNB2
|
0.02114 |
| ECM.receptor interaction |
4 genes: HSPG2, ITGA2, LAMA4, SV2B
|
0.02281 |
| Tight junction |
5 genes: PRKCA, ASH1L, ACTB, SPTAN1, ACTN1
|
0.02713 |
| Natural killer cell mediated cytotoxicity |
5 genes: FYN, KLRD1, PPP3CA, PRKCA, PTPN11
|
0.02949 |
| Glycosaminoglycan biosynthesis . chondroitin sulfate |
2 genes: CHST11, CHST3
|
0.03118 |
| Fc gamma R.mediated phagocytosis |
4 genes: WASF2, INPP5D, PRKCA, PIP5K1B
|
0.03256 |
| Nitrogen metabolism |
2 genes: CPS1, CA12
|
0.03387 |
| Endocytosis |
6 genes: EHD1, CCR5, ARFGAP3, SMAP2, PIP5K1B, GIT2
|
0.04474 |
| Hippo signaling pathway |
5 genes: WWTR1, DLG2, BMPR2, FZD1, ACTB
|
0.0463 |